Life sciences and health care M&A trends and investment opportunities (US leaders)

- Susan Dettmar, principal, US leader, M&A consultative services, Deloitte Consulting LLP
- Simon Gisby, managing director, life sciences and health care national practice leader, Deloitte Corporate Finance LLC
- Phil Pfrang, partner, global life sciences and health care M&A transaction services leader, Deloitte & Touche LLP

M&A trends in oncology

- Varun Budhiraja, principal, Deloitte Consulting LLP
- Susan Dettmar, principal, US leader, M&A consultative services, Deloitte Consulting LLP

Digital therapeutics: Driving convergence between pharma and technology

- Brett Davis, principal, Deloitte Consulting LLP
- Susan Dettmar, principal, US leader, M&A consultative services, Deloitte Consulting LLP

The future of health: Navigating the evolving ecosystem

- Neal Batra, principal, Deloitte Consulting LLP
- Simon Gisby, managing director, life sciences and health care national practice leader, Deloitte Corporate Finance LLC
- Amry Junaideen, partner, life sciences and health care leader, Deloitte & Touche LLP

Investing in health tech: Health care’s new frontier

- Simon Gisby, managing director, life sciences and health care national practice leader, Deloitte Corporate Finance LLC
- James Gorayeb, partner, life science and health care, Deloitte & Touche LLP
- Pete Micca, partner, life sciences and health care, Deloitte & Touche LLP

Behavioral health sector investing

- Bill Siren, managing director, Deloitte Consulting LLP
- Rishi Patel, senior manager, Deloitte & Touche LLP

Maximizing value in a divestiture process: How to be successful in sale processes, carveouts, spins and IPOs

- Chris Caruso, partner, M&A transaction services, Deloitte & Touche LLP
- Nick Cirignano, managing director, life sciences and health care, Deloitte Corporate Finance LLP
- Jenny Gilmore, managing director, advisory, Deloitte & Touche LLP
- Jeremy Martin, senior manager, M&A transaction services, Deloitte & Touche LLP

Winning strategies for commercial success of nextgen therapies

- Amit Agarwal, managing director, Deloitte Consulting LLP
- Hussain Mooraj, principal, Deloitte Consulting LLP
- Sanjay Srivastava, PhD, senior manager, Deloitte Consulting LLP

Post-acute Care (“PAC”): Alignment dynamics and emerging trends in continuing care network development

- Lisa Ahern, principal, Deloitte Consulting LLP
- Todd Patnode, managing director, leader of Deloitte’s health care turnaround and restructuring practice, Deloitte CRG
- Dan Wilson, managing director, Deloitte CRG

Alternative payment models: What’s driving the wave of change with providers and payers

- Mark Bethke, managing director, Deloitte Consulting LLP
- Kumar Kanisan, senior manager, Deloitte Consulting LLP

From doing digital to being digital: How life sciences companies can move beyond experimentation to realize value

- Jonathan Fox, specialist leader, Deloitte Consulting LLP
- Greg Reh, principal, US life sciences and DTTL global life sciences sector lead, Deloitte Consulting LLP
- Chris Zant, principal, life sciences and health care, Deloitte Consulting LLP
Global life sciences and health care M&A trends and investment opportunities (global leaders)

- Xander Alpherts, corporate finance partner, health care M&A leader, Deloitte Australia
- Simon Brew, partner, consulting, Deloitte United Kingdom
- Carrie Chen, partner, corporate finance, China financial advisory leader, Deloitte China
- Tai Chen, partner, global technology alliances practice leader, Deloitte Israel
- Jason Ding, managing director, corporate finance, life sciences and health care practice, Deloitte Canada
- Kauhisa Go, managing director, corporate finance, Deloitte Japan
- Stav Gregoriou, director, M&A transaction services, Deloitte United Kingdom
- Tim Hayden, senior manager, M&A transaction services, Deloitte Canada
- Masafumi Ito, partner, M&A transaction services, Deloitte Japan
- David Jones, partner, UK corporate finance, European financial advisory leader, Deloitte United Kingdom
- Andy Khanna, partner, corporate finance, financial advisory life sciences leader, Deloitte India
- Andreas Korten, partner, M&A transaction services, Deloitte Germany
- Sebastian Krolop, partner, consulting, Deloitte Germany
- Susana Novo, partner, México life sciences and health care corporate finance lead, Deloitte México
- Phil Pfrang, partner, global life sciences and health care M&A transaction services leader, Deloitte & Touche LLP
- Jan Rattay, partner, M&A transaction services, Deloitte United Kingdom
- Anna Samanta, partner, EMEA life sciences M&A lead, Deloitte Switzerland
- Amar Shah, director, Deloitte United Kingdom
- Bill Stamatis, Canadian life sciences and health care lead partner, Deloitte Canada
- Michael van der Boom, partner, M&A transaction services, Deloitte Switzerland
- Dr. Loke Wai Chiong, partner, Southeast Asia health care sector leader, Deloitte Singapore

Disruptive and innovation driven M&A

- Anna Samanta, partner, EMEA life sciences M&A lead, Deloitte Switzerland
- Michael van der Boom, partner, M&A transaction services, Deloitte Switzerland

Life sciences & health care: Regulatory update

- Daniel Esquibel, senior manager, Deloitte & Touche LLP

Cybersecurity in the digital health age: What every investor/acquirer needs to know

- Will Engelbrecht, principal, Deloitte Consulting LLP
- Russell Jones, partner, Deloitte risk and financial advisory, Deloitte & Touche LLP

Outsourced pharma services: Sectors and companies to watch

- Dawn Anderson, managing director, R&D life sciences, Deloitte Consulting LLP
- Stav Gregoriou, director, transaction services, Deloitte LLP
- Neil Lesser, principal, Deloitte Consulting LLP
- Amar Shah, director, life sciences and health care, Deloitte LLP

Physician practice management and specialty EMR

- Dorrie Guest, managing director, Deloitte Consulting LLP
- Nick Massiello, specialist leader, Deloitte Consulting LLP

Can overseas tech acquisition cure China’s health care woes?

- Kenneth J. DeWoskin, Ph.D., senior advisor, Chinese services group, Deloitte Services LP

Disruption and investment strategies in the generics pharma industry

- Faith Glazier, principal, life science generics segment leader, Deloitte LLP

Life sciences and health care return on capital analysis

- Teresa Leste, principal, strategy practice leader, Deloitte Consulting LLP

Outsourced services to health plans

- James Gorayeb, partner, life science and health care, Deloitte & Touche LLP

Cannabis industry overview

This publication contains general information only and Deloitte is not, by means of this publication, rendering accounting, business, financial, investment, legal, tax, or other professional advice or services. This publication is not a substitute for such professional advice or services, nor should it be used as a basis for any decision or action that may affect your business. Before making any decision or taking any action that may affect your business, you should consult a qualified professional advisor. Deloitte shall not be responsible for any loss sustained by any person who relies on this publication.

About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.